Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients on apixaban, dabigatran, rivaroxaban: cohorts comprising new initiators and/or switchers from warfarin

被引：0
|
作者：
Tepper, P. [1 ]
Mardekian, J. [2 ]
Masseria, C. [2 ]
Phatak, H. [3 ]
Kamble, S. [3 ]
Abdulsattar, Y. [2 ]
Petkun, W. [3 ]
Lip, G. Y. H. [4 ]
机构：
[1] Univ Pittsburgh, Epidemiol, Pittsburgh, PA USA
[2] Pfizer Inc, New York, NY USA
[3] Bristol Myers Squibb Co, Princeton, NJ USA
[4] Univ Birmingham, Birmingham, W Midlands, England
来源：
EUROPEAN HEART JOURNAL | 2015年 / 36卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1975
引用
收藏
页码：339 / 339
页数：1
相关论文
共 50 条
  • [21] Risk of Stroke and Major Bleeding for Dabigatran, Rivaroxaban, and Warfarin Compared to Apixaban Among Non-Valvular Atrial Fibrillation Patients in the United States Medicare Population
    Amin, Alpesh
    Keshishian, Allison
    Trocio, Jeffrey
    Dina, Oluwaseyi
    Le, Hannah
    Rosenblatt, Lisa
    Liu, Xianchen
    Mardekian, Jack
    Zhang, Qisu
    Baser, Onur
    Vo, Lien
    CIRCULATION, 2017, 136
  • [22] Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation
    Andersson, Niklas W.
    Svanstrom, Henrik
    Lund, Marie
    Pasternak, Bjorn
    Melbye, Mads
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2018, 268 : 113 - 119
  • [23] Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study
    Kjerpeseth, Lars J.
    Selmer, Randi
    Ariansen, Inger
    Karlstad, Oystein
    Ellekjaer, Hanne
    Skovlund, Eva
    PLOS ONE, 2019, 14 (08):
  • [24] Bleeding risk with dabigatran, rivaroxaban, warfarin, and antiplatelet agent in Asians with non-valvular atrial fibrillation
    Chan, Yi-Hsin
    Yeh, Yung-Hsin
    Tu, Hui-Tzu
    Kuo, Chi-Tai
    Chang, Shang-Hung
    Wu, Lung-Sheng
    Lee, Hsin-Fu
    See, Lai-Chu
    ONCOTARGET, 2017, 8 (58) : 98898 - 98917
  • [25] Comparative Effectiveness of Dabigatran and Rivaroxaban versus Warfarin in Patients With Non-Valvular Atrial Fibrillation
    Bengtson, Lindsay
    Chen, Lin
    MacLehose, Richard
    Lutsey, Pamela
    Alonso, Alvaro
    CIRCULATION, 2014, 130
  • [26] Dabigatran, rivaroxaban, and apixaban are superior to warfarin in Asian patients with non-valvular atrial fibrillation: An updated meta-analysis
    Li, Wei-Jia
    Archontakis-Barakakis, Paraschos
    Palaiodimos, Leonidas
    Kalaitzoglou, Dimitrios
    Tzelves, Lazaros
    Manolopoulos, Apostolos
    Wang, Yu-Chiang
    Giannopoulos, Stefanos
    Faillace, Robert
    Kokkinidis, Damianos G.
    WORLD JOURNAL OF CARDIOLOGY, 2021, 13 (04): : 82 - 94
  • [27] Factors associated with bleeding events in patients on rivaroxaban for non-valvular atrial fibrillation: A real-world experience
    Akhtar, Tauseef
    Fratti, Juan Del Cid
    Mattumpuram, Jishanth
    Fugar, Setri
    Uprety, Alok
    Nwaichi, Chineme
    Torres, Andrea
    Mann, Hashim
    Golzar, Yasmeen
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2020, 320 : 78 - 82
  • [28] Early Comparison of Major Bleeding, Stroke and Associated Medical Costs Among Treatment-Naive Non-Valvular Atrial Fibrillation Patients Initiating Apixaban, Dabigatran, Rivaroxaban or Warfarin
    Alpesh, Amin N.
    Keshishian, Allison
    Xie, Lin
    Baser, Onur
    Price, Kwanza
    Vo, Lien
    Singh, Prianka
    Bruno, Amanda
    Mardekian, Jack
    Tan, Wilson
    Singhal, Shalabh
    Patel, Chad
    Odell, Kevin
    Trocio, Jeffrey
    BLOOD, 2015, 126 (23)
  • [29] Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in "real-world" clinical practice
    Li, Xiaoyan
    Deitelzweig, Steve
    Keshishian, Allison
    Hamilton, Melissa
    Horblyuk, Ruslan
    Gupta, Kiran
    Luo, Xuemei
    Mardekian, Jack
    Friend, Keith
    Nadkarni, Anagha
    Pan, Xianying
    Lip, Gregory Y. H.
    THROMBOSIS AND HAEMOSTASIS, 2017, 117 (06) : 1072 - 1082
  • [30] Persistence of Dabigatran Versus Warfarin Therapy in Patients with Non-valvular Atrial Fibrillation in the Real-world Clinical Practice
    Lau, Wallis C. Y.
    Chan, Esther W.
    Wong, Ian C. K.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 382 - 382
12345